PAM
TCRX icon

Panagora Asset Management’s TScan Therapeutics TCRX Stock Holding History

Panagora Asset Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,797
Closed -$29.1K – 1299
2026
Q1 		$29.1K Buy
28,797
+3,541
+14% +$3.78K ﹤0.01% 1155
2025
Q4 		$25.3K Buy
+25,256
New +$36.6K ﹤0.01% 1176

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Panagora Asset Management's TCRX Position: Q2 2026 in Review

Panagora Asset Management sold out of TScan Therapeutics (TCRX) in Q2 2026, closing a stake of 28,797 shares — an estimated $29.1K sold.

Panagora Asset Management first reported a position in TCRX in Q4 2025 and held it in 2 quarters. The position peaked at $29.1K in Q1 2026. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Panagora Asset Management reported no remaining TScan Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Panagora Asset Management sold 28,797 TScan Therapeutics shares in Q2 2026, an estimated $29.1K.
  • Panagora Asset Management first reported a position in TScan Therapeutics in Q4 2025 and held it in 2 quarters.
  • Panagora Asset Management's TScan Therapeutics position peaked at $29.1K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.